Full-Time

VP – Biometrics

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$365k - $403kAnnually

Expert

San Bruno, CA, USA

Category
Public Health
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • Ph.D. in Statistics or related fields and 15+ years of pharmaceutical industry experience or Master in Statistics and 20+ years of comparable experience
  • Expert knowledge of ICH and other regulatory development guidelines.
  • Experience in recruiting, coaching, and developing talented team members.
  • Deep understanding of mathematical and statistical principles; demonstrated proficiency in at least one statistical analysis software (SAS preferably). Knowledge of other statistical software is a plus.
  • Experience in clinical development of wide range of therapeutic areas is a plus.
  • Stellar communication and presentation skills. Must be able to articulate with non-statisticians to interpret and explain statistical findings.
  • Excellent organizational and problem-solving skills.
  • Proven leadership skills and must work effectively in a team environment.
  • Knowledge of good biometrics procedures is desired.
Responsibilities
  • Define and execute the strategic vision for the Biometrics Department.
  • Establish organizational structure for biometrics department, including Biostatistics, Statistical Programming, Data Management, and Clinical Systems functions. Lead and develop Biometrics employees.
  • Oversee and coordinate all biometrics activities to support of clinical development projects as well as deliver innovative study designs and analysis plans, ensuring sound biometrics principles and compliance with regulatory guidelines.
  • Advises on statistical issues associated with the design and analysis of clinical trials and responsible for biometrics input on all major documents including, clinical development plans, protocols, data collection methodologies, clinical study reports and summaries of clinical safety and efficacy for regulatory filings.
  • Guide application of epidemiologic methods to analyze observational/real world data to strengthen submission evidence and support drug development.
  • Provides review and guidance on statistical aspects, new programming, database technologies, clinical systems and standards of all FDA/EMEA regulations and ICH & GCP guidelines.
  • Senior biostatistics representative supports protocol/clinical document review, strategic- and partner joint- development activities, drug safety, and publication activities.
  • Collaborate with other senior development leaders ensure consistency of development work standards intellectually, challenging assumptions and sharing ideas.
  • Provide leadership for sponsor/CRO activities, relationships and escalation resolution.
  • Interact with FDA/EMA and other health authorities to ensure clinical studies meet regulatory requirements and to ensure ongoing agreement on project development.
  • Support the development and implementation of best practices, SOPs, standards, work instructions and policies for biostatistics.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a range of drugs in clinical trials, including omecamtiv mecarbil and reldesemtiv, aimed at treating conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from debilitating muscle-related conditions.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase III results for aficamten could lead to successful market entry.
  • Strategic funding collaboration with Royalty Pharma provides significant financial support.
  • Growing awareness of hypertrophic cardiomyopathy can increase demand for treatments.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos poses a threat to aficamten.
  • Reliance on successful clinical trial outcomes could impact financial stability.
  • High cost of drug development indicates potential financial strain if revenues falter.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and reldesemtiv.
  • Cytokinetics conducts over 50 clinical trials, demonstrating commitment to scientific research.

Help us improve and share your feedback! Did you find this helpful?